scholarly journals Clinicopathologic factor and Lymphovascular Invasion in Breast cancer

2006 ◽  
Vol 9 (4) ◽  
pp. 317 ◽  
Author(s):  
Ja Seong Bae ◽  
Byung Joo Song ◽  
Mi la Kim ◽  
Seok Hyo Chang ◽  
Han Seong Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymphovascular Invasion ◽  
Clinicopathologic Factor

Gene expression associated with lymphovascular invasion and genomic risk in early-stage breast cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 559-559
Author(s):  
Nina D'Abreo ◽  
Abhinav Rohatgi ◽  
Douglas Kanter Marks ◽  
Heather Kling ◽  
Josien Haan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Cell Adhesion ◽  
Clinical Outcomes ◽  
Lymphovascular Invasion ◽  
Group Analysis ◽  
Enrichment Analysis ◽  
Functional Enrichment ◽  
Tumor Type ◽  
Luminal B

559 Background: Lymphovascular invasion (LVI), the passage of carcinoma cells through lymphatic and blood vessels, is an important early step in metastasis; however, LVI is excluded from most breast cancer (BC) clinical risk assessments. Previous studies assessed the prognostic value of LVI to estimate clinical outcomes. To gain understanding of the molecular basis of LVI, we evaluated differentially expressed genes (DEGs) between tumors with LVI versus those without LVI, stratified by the 70-gene signature (MammaPrint/MP) and 80-gene molecular subtyping signature (BluePrint/BP). Methods: The prospective, observational FLEX Study (NCT03053193) includes stage I-III BC patients who receive MP/BP testing and consent to full transcriptome and clinical data collection. Patients with LVI (n=581) and without LVI (n=600, randomly selected), enrolled from 2017 to present, were included. LVI was assessed by local pathology laboratories. Differential gene expression analysis of 44k Agilent microarray data was performed with R limma package. DEGs were compared within all samples, BP Luminal subtype, MP risk groups (Low Risk [LR]/Luminal A and High Risk [HR]/Luminal B), and by lymph node (LN) status. DEGs with FDR<0.05 were considered significant. Results: Of tumors with LVI (LVI+), 66% were MP HR; notably, 51% of tumors without LVI (LVI-) were MP HR. LVI was associated with larger T stage, LN involvement, high grade, negative ER status by IHC, and younger patient age (LVI+ vs. LVI-, p<0.05 for all comparisons). Patient ethnicity, obesity, and tumor type did not differ by LVI status; however, prevalence of type 2 diabetes trended higher in patients with LVI+ HR tumors (21%), compared with LVI- HR (15%, p=0.09) and LVI+ LR (11%, p=0.004). There were significant transcriptomic differences between LVI+ and LVI, with most DEGs evident in the Luminal B subset. DEGs in LVI+, LN-negative (LN-) tumors overlapped substantially with the overall Luminal group analysis. Functional enrichment analysis showed dysregulation of cell cycle, extracellular matrix (ECM) organization, cell adhesion, and cytokine receptor pathways. Gene sets related to insulin growth factor pathways were also enriched in LVI+ tumors. Conclusions: DEGs associated with LVI were primarily found in MP HR Luminal, LN-negative tumors; enrichment analysis suggested dysregulation of ECM organization and cell adhesion pathways, consistent with previous reports. DEGs were not associated with LVI presence in LN+ tumors, suggesting that LVI assessment may be less relevant in LN+ breast cancer. Future studies will assess clinical outcomes, as well as LVI-associated gene expression in BP Basal- and HER2-type tumors. However, the current analysis indicates few DEGs in LVI+ MP LR tumors; thus, the potential prognostic information gained from LVI-associated gene expression is likely already captured by the MP and BP signatures. Clinical trial information: NCT03053193.

Prognostic Role of Lymphovascular Invasion in Patients with Early Breast Cancer

2021 ◽  
Author(s):  
M. Akrami ◽  
A. Meshksar ◽  
Johari M. Ghoddusi ◽  
M. M. Safarpour ◽  
S. Tahmasebi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Lymphovascular Invasion ◽  
Prognostic Role

scholarly journals Value of digital mammography in predicting lymphovascular invasion of breast cancer

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Zhuangsheng Liu ◽  
Ruqiong Li ◽  
Keming Liang ◽  
Junhao Chen ◽  
Xiangmeng Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Digital Mammography ◽  
Lymphovascular Invasion

Does lymphovascular invasion affects the outcome of axilla down staging in node positive operable invasive breast cancer?

2019 ◽  
Vol 45 (2) ◽  
pp. e26
Author(s):  
A. Saad Abdalla ◽  
A. Asaad ◽  
P. Idaewor ◽  
M. Barron ◽  
M. Elamass ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Breast Cancer ◽  
Lymphovascular Invasion ◽  
Node Positive

Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?

Breast Cancer ◽  
2010 ◽  
Vol 18 (4) ◽  
pp. 309-313 ◽  
Author(s):  
Takayoshi Uematsu ◽  
Masako Kasami ◽  
Junichiro Watanabe ◽  
Kaoru Takahashi ◽  
Seiji Yamasaki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Lymphovascular Invasion ◽  
Chemotherapy Efficacy

Post IORT seroma complication in breast cancer surgery

2020 ◽  
pp. 1-7
Author(s):  
Maha Abdel Hadi ◽  
Afnan Al-Muhanna ◽  
Lina Abu Arida ◽  
Dina Lutfi
Keyword(s):  
Breast Cancer ◽  
Lymphovascular Invasion ◽  
Tumour Size ◽  
Nodal Status ◽  
Histological Diagnosis ◽  
Tumour Grade ◽  
Receptor Status ◽  
Life Threatening ◽  
Radiotherapy Treatment

Abstract Background: Intraoperative radiotherapy (IORT) has gained popularity over recent years due to its impact on shortening the radiotherapy treatment time for early breast cancer. It has certainly proven effective as an exclusive treatment or when combined with whole breast irradiation (WBIR). Seroma is a common non-life-threatening complication that may delay treatment and impose challenges on radiological diagnostic follow-up. Aim: To review and compare the occurrence of seroma in patients who received exclusive IORT or when combined with WBIR and to outline the diagnostic challenges encountered during radiological follow-up. Materials and methods: Based on strict selection criteria, all eligible patients who received IORT ± WBIR treatment between 2012 and 2019 in a university hospital setting were included. Demographic data, histological diagnosis, tumour size, tumour grade, lymphovascular invasion, nodal status, receptor status, treatment with neoadjuvant hormonal chemotherapy, applicator size, dose used, duration of radiotherapy treatment, timing of seroma development and duration of seroma were documented. Both clinical and radiological follow-up were exercised in all patients. Results: The total number of patients treated with breast conserving surgery (BCS) and IORT was 86. Age ranged between 31 and 75 years with the median age of 51 years. Patients treated exclusively with IORT were 39 (45%) while those who received the IORT as a boost were 47 (55%). Seroma was observed in 39(45%) of both IORT and IORT\WBIR patients. Those included 15(38%) of the exclusive IORT treated patients and 24 (62%) of those treated as a boost. Duration of asymptomatic seroma ranged from 6 months to 6 years. Repeated aspiration was performed in 2 (5%) patients. Postoperative seroma occurred independent of age histological diagnosis, tumour size, tumour grade, lymphovascular invasion, nodal status, receptor status, treatment with neoadjuvant hormonal\chemotherapy, applicator size, dose used or duration of radiotherapy treatment. All reviewed patients have shown increased risk of developing seroma; however, an increased incidence of seroma in the IORT + WBIR treated patients was higher than those who received exclusive IORT treatment. Conclusion: Postoperative seroma is a common non-life-threatening entity that occasionally may lead to delay in the subsequent treatment plan. IORT is a safe modality with many benefits; however, it may increase the risk of seroma formation independent of the clinical parameters. Promoting the expertise in post IORT breast imaging aids in overcoming diagnostic challenges.

Sign in / Sign up

Export Citation Format

Share Document